^
Association details:
| Biomarker: | CD19 negative + CD20 negative + CD22 negative |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Darzalex (daratumumab) (CD38 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
Published date:
12/20/2021
Excerpt:
We report the successful treatment of a 26-year-old man who suffered R/R, CD19, CD20, and CD22 negative B-ALL targeting Bcl-2 and CD38 by combining venetoclax and daratumumab with chemotherapy.
DOI:
10.1186/s40364-021-00343-3
